Drug Profile
Research programme: psoriasis therapeutics - AbbVie/NuMedii
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Allergan; NuMedii
- Developer AbbVie; NuMedii
- Class Antipsoriatics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Psoriasis in USA
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 19 Jul 2016 Preclinical trials in Psoriasis in USA (unspecified route)